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Abstract
Aims—When patients choose percutaneous coronary intervention (PCI) over coronary artery
bypass grafting (CABG), they accept an increased long-term risk of repeat revascularization in
exchange for short term morbidity benefits. This paper quantifies the risk-benefit trade-off faced
by patients with multiple vessel coronary artery disease.
Methods and Results—Data from the Arterial Revascularization Therapies Study are used to
generate risk-benefit acceptability curves for PCI versus CABG. Risks are measured by the long-
term likelihood of repeat revascularization while benefits are measured by short term reductions in
pain or improvements in health-related quality of life (HRQL). PCI patients faced a risk of 0.81
additional revascularization events over three years in exchange for being pain-free at one month.
A patient would need to be willing to tolerate a risk of 1.06 additional revascularization events at
three years, in exchange for being pain free at one month to be 95% confident that choosing PCI
over CABG is risk-effective for him/her.
Conclusions—The risk-benefit framework outlined in this study provides information to enable
physicians to help their patients weigh directly each procedure’s risks and benefits. While trade-
offs are typically measured in quality-adjusted life years, using pain reduction to reflect benefits
may provide a more tangible framework for patients.
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Introduction
The optimal mechanical revascularization technique for multivessel coronary disease
(MVD) remains contentious, with advocates supporting both percutaneous coronary
intervention with insertion of stents (PCI) and coronary artery bypass grafting (CABG).
Patients choose a procedure after consultation with physicians and may weigh a number of
considerations in making their decision. Trends in the United States and elsewhere show that
the volume of percutaneous procedures has been increasing while CABG rates decline.[1,2]
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These data indicate a growing preference for PCI over CABG for many patients and their
physicians, especially for persons age 65 and older.[3]
Traditional cost-effectiveness analysis is useful for determining the societal benefit of these
procedures, and this avenue of research has been incorporated in a number of comparisons
of PCI and CABG.[4] [5] However, for patients with low cost sharing requirements for both
procedures, the choice may be based on the valuation of benefits and risks rather than
financial consideration. Clinical trial evidence indicates that both CABG and PCI increase
health-related quality of life (HRQL) for patients with MVD. In the long-run, however,
CABG shows substantially lower rates of revascularization when compared with bare metal
stenting (PCI).[6] Receiving these deferred benefits of reduced rates of repeat
revascularization requires accepting higher morbidity such as delayed relief from pain or
improvement in HRQL in the time period immediately following the procedure.
Economists have become interested in using probabilistic methods to portray the trade-off
between risks and benefits as well as the implicit valuation that patients make when one
technique is chosen over a competitor. For example, probabilistic simulation modeling has
been used to estimate the joint density of therapeutic risks and benefits from two
pharmacological prophylactic treatments for deep-vein thrombosis.[7] In this study, we use
clinical data from the Arterial Revascularization Therapy Study (ARTS) to estimate the
trade-off between the benefit of quick reductions in post-procedure pain and HRQL when
choosing PCI versus the increased risk of repeat revascularization. Specifically, this analysis
uses a risk-benefit acceptability curve (RBAC), which is analogous to the cost-effectiveness
acceptability curves used to portray uncertainty in the economic evaluation of health care
technologies.[8] The RBAC provides estimates of the probability that a particular approach
such as PCI is viewed by the consumer as being risk-effective (i.e., having greater value of
benefits than cost of risks, analogous to cost-effectiveness) over different preference
thresholds for the risk-benefit trade-offs identified. The estimates provided may be useful to
physicians in explaining trade-offs between risks and benefits of alternative treatments to
their patients, and the methodology can be applied to the current generation of PCI versus
CABG studies as more complete data become available.
Methods
Between April 1997 and June 1998, ARTS randomized 1205 patients with MVD to receive
PCI with bare metal stent implantation (n=600) or CABG (n=605).[5] Key details of the
original study relevant for this analysis are the inclusion/exclusion criteria and the data
collection strategy. The indications for revascularization for enrollment in ARTS included
silent ischemia, stable or unstable angina pectoris, and the presence of at least 2 de novo
lesions located in different major epicardial coronary arteries. Exclusion criteria included
left ventricular ejection fraction <30%, left main stenosis, history of cerebrovascular
accident (CVA), transmural myocardial infarction (MI) within the preceding week, severe
hepatic or renal disease, and need for concomitant major surgery.[9] All patients gave
written, informed consent. Follow-up information was obtained for patients at 1, 6, 12, and
36 months post-randomization, and the EuroQol EQ-5D instrument was administered to
patients at each time point. More PCI patients completed the EQ-5D at 1 month than did
CABG patients (93.5% versus 88.8%, p = 0.005); by 6 months, the difference was not
significant and remained so for the rest of the follow-up period (90.2% vs 87.8%, p=0.22).
All other data completion rates were comparable between treatment groups.
A binary variable indicating the presence or absence of clinical events was used to represent
the risk in the decision to undergo PCI. Risk variables were calculated for three outcomes at
12 and 36 months post-randomization: (1) additional mechanical revascularization after the
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randomized therapy; (2) additional PCI; and (3) additional CABG. Separate analysis of
death, CVA and MI are not provided because their incidence did not differ in the ARTS
trial, though disagreement remains about whether these outcomes differ between the two
procedures. We used three measures to quantify the quality of life benefits of PCI. The pain/
discomfort question on the EQ-5D was recoded to a binary variable indicating absence or
presence of pain at the time of interview. For a more comprehensive view, a preference -
weighted composite health-related quality of life measure (HRQL) was calculated from the
EQ-5D survey responses.[10] Patients who did not complete the EQ-5D because they died
prior to its administration were assumed to have a HRQL of zero for all subsequent time
points. The HRQL measure was also used to estimate quality-adjusted life years (QALYs)
post-intervention; since HRQL was only measured at four points post-randomization, we
approximated QALYs using a linear area under the curve approximation (except for the first
month, where the patient’s HRQL at 1 month post randomization was used to calculate the
entire first month of QALY since PCI offers such immediate pain relief relative to CABG).
Incremental risk was calculated as the difference in the proportions of patients experiencing
additional revascularization for patients assigned to PCI versus CABG. Similarly,
incremental benefit was calculated as the difference in proportions of patients reporting
being free from pain and the difference in mean HRQL scores. Incremental risk-benefit
ratios (IRBR) for various follow-up points in time were calculated by dividing incremental
risk by incremental benefit:
(1)
Bootstrapping with 5,000 replicates was conducted to form risk-benefit acceptability curves
(RBAC) for each combination of selected risk time points (12 and 36 months) and one
month benefit.[8] A longer time frame (up to 3 years) was chosen for risks while a shorter
time frame was chosen for benefits because differences in benefits (pain or HRQL) were
concentrated in the first few months after initial revascularization (see Figures 1A and 1B).
All inference statistics were conducted at a two-tailed alpha level of 0.05, and results were
analyzed on an intention to treat basis. Data analysis was conducted in SAS version 9.1.3
(SAS Institute, Cary, NC) and Stata version 10.1 (Statacorp, College Station, TX).
Rather than attempt to explicitly discount pain or clinical events benefits, we compared the
long-term risks of PCI with its short-term benefits. As discussed later, discounting would
increase the relative value of PCI because of greater short term pain reduction benefits in
contrast to the benefits from CABG that take longer to accrue.
Results
As previously reported, rates of revascularization were higher among patients randomized to
PCI than CABG, with the incremental risk for PCI versus CABG increasing from 17.2% to
20.2% when moving from 1 to 3 years post-randomization (Table 1).[6] [11] At three years
post randomization, of the 160 PCI patients who had experienced additional
revascularization 15 (2.5% of trial arm) had experienced both an additional PCI and an
additional CABG while of the 39 CABG patients with repeat revascularizations only 2
(0.3%) had experienced both procedures after their initial treatment.
PCI patients were more likely to be free from pain and had higher HRQL scores shortly after
randomization, though the effects were no longer statistically significant by six months after
intervention. Table 1 shows that the incremental benefit of PCI decreases (from 0.25 to 0.04
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on the freedom from pain measure and from 6.3 to −0.9 on the HRQL measure) when
moving from the 1 month to 6 month time point, as many CABG patients recovered from
the immediate post-procedure pain and HRQL impairment that occurs during the first few
months following CABG. Figures 1A and 1B illustrate this trend graphically and show that
composite HRQL from CABG reaches that of PCI slightly earlier than does freedom from
pain, with both measures statistically equal from both procedures by 12 months post
randomization. When QALYs are calculated using the HRQL scores, the difference in
QALYs is minimal and not statistically significant after six months. Since repeat
revascularizations accrue over time but significant differences in benefits occur only at one
month after initial revascularization, we focus our comparisons on the trade-off of long-term
risk for short-term benefit.
Together, the increased risk of revascularization from PCI and benefit trends for both
procedures lead to increasing risk-benefit ratios as time from initial treatment randomization
increases (Table 2). Bootstrapped estimates of the incremental risks and benefits and the
distribution of the incremental risk/benefit ratio illustrate the trade-off more completely. All
of the sampled incremental risk and benefit estimates were positive, meaning there was
always a tradeoff between PCI and CABG and the IRBRs were always positive. As shown
in the last column of Table 2 (bottom half), our data indicate that a patient or his/her
physician would need to be willing to tolerate a risk of 1.06 additional revascularizations,
including risk of 0.76 additional repeat PCI events and 0.44 additional CABG events, at 3
years in exchange for being pain free at 1 month in order to be 95% confident that choosing
PCI over CABG is risk-effective for him/her. (By risk-effective, we mean that the risk is
worth the benefit.) Similarly, for each 1 percentage point improvement in HRQL at 1 month
post randomization, a patient would need to be willing to tolerate 4.8 additional
revascularizations to be 95% confident that they are making a risk-effective choice in
choosing PCI.
Figure 2 demonstrates the information in Table 2 visually through the formation of the risk-
benefit acceptability curves (RBACs) from the distributions of incremental risk-benefit
ratios. The RBAC illustrates the probability that PCI is risk-effective given a particular risk-
benefit ratio threshold. [12] Each RBAC in Figure 2 represents the cumulative density of a
single ratio of risk and benefit variables (the proportion of sampled ratios less than or equal
to the specified ratio). Consequently, movements along the curve from the left to the right
represent a willingness to accept a higher level of risk of revascularization from PCI in
return for the immediate relief (i.e., reduction in pain or improvement in HRQL) from PCI
relative to CABG. Discounting of benefits and risks (not done for simplicity of presentation)
would shift the curves more to the left since the pain reduction from CABG is delayed
relative to PCI.
We noted earlier that more PCI patients completed the EQ-5D at 1 month than did CABG
patients. The lower response rates for the EQ-5D at 1 month post randomization among
CABG patients likely leads to an underestimation of the pain reduction benefits of PCI, as
patients with high pain at one month were probably less likely to complete surveys. To
assess this possible bias, we recalculated the risk benefit ratios under the assumption that the
difference in response rate between CABG and PCI patients at 1 month after randomization
(4.7 percent) was comprised entirely of patients in pain (the least favorable case for CABG).
Our point estimates of the risk benefit ratios would in this case overestimate the ratio by
only 7.4%, indicating that any bias from differential response rates for CABG and PCI
patients at 1 month is not substantial.
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This report uses risk-benefit ratio estimation and the corresponding risk-benefit acceptability
curves to model the tradeoff between PCI and CABG. We model the choice of PCI over
CABG as that of accepting greater long-term risk of additional revascularization in
exchange for reduced post-procedure morbidity, specifically pain and composite HRQL.
Rather than discount risks or benefits, we explicitly compared short term benefits and long
term risks by comparing benefits at 1 and 6 months with risks at 12 and 36 months. In order
for patients or their physicians to be 95 percent confident that their decision is risk-effective,
a patient choosing PCI over CABG would need to be willing to accept the risk of 1.06
additional revascularizations over the next 3 years per patient benefiting by being free from
pain at 1 month post-randomization. Analogously; a patient would need to accept 4.8
additional procedures per percentage point increase in HRQL.
Although the trial data are one decade old, the objective of this analysis is to develop a
methodology that can enable more informed decision making on the part of patients and
their physicians in choosing between PCI and CABG when neither procedure has a
compelling indication or contraindication. Individual patients will value the trade-off
differently; for some, exchanging the increased risk of repeat PCI or CABG to obtain short-
term pain relief and HRQL increases will be acceptable, while others may prefer to endure
short-term pain to obtain a higher probability of avoiding a subsequent revascularization.
Additionally, patients may prefer to risk undergoing multiple PCI procedures rather than a
single CABG, or they may prefer to avoid the risk of requiring CABG subsequent to PCI
and instead have CABG initially.
The interpretation of RBACs has generally followed Bayesian guidelines. This approach has
advantages from a policymaker’s perspective, because it allows for the determination of
whether an intervention is risk effective given a specified tolerance for risk. This delineation
has clear value in exercises such as determining how much risk of severe adverse events
would have to be tolerated to receive benefits. Composite HRQL measures generated from
the EQ-5D provide a more comprehensive view of a patient’s status than outcomes based
strictly on freedom from pain. Yet the interpretation of HRQL is less intuitive, especially for
patients. We suggest that the freedom of pain measure, while a simplification of HRQL,
provides a useful way for physicians to work with patients to compare these two procedures,
as presence and absence of pain is intuitive for most patients and providers. Distributions of
risk-benefit ratios can provide patients and physicians with a sense of the trade-off between
risks and benefits in direct comparison, not simply the separate magnitudes of risks and
benefits. Patients would be best informed by being given both the risk-benefit ratio and the
size of the absolute risks and benefits. The changes at the margin are likely most relevant for
policy makers, and the fact that the statistically significant differences in outcome occur for
just a short period after initial revascularization mean that the absolute increase in QALYs is
very small.
Our study is not without limitations, especially in terms of applying the results in current
clinical practice. Conceptually, our model depends on the assumption that the primary risk a
patient experiences when choosing PCI over CABG is that of repeat revascularization, and
the primary benefit is decreased pain. While most clinicians accept those risks and benefits
as correct, especially with the use of bare metal stents, assertions about differences in rates
of death and more severe complications are more contentious.[13–16] Furthermore, drug
eluting stents have reduced risk of restenosis compared with that of bare metal stents,
although controversy remains about the magnitude of this effect and potential increased risk
of thrombotic events,[17–19] though longer-term follow-up data are not yet available. The
results of the SYNTAX and FREEDOM trials, among others, will explore in detail the
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different risks and benefits of PCI with drug eluting stent insertion when compared with
CABG in patients with MVD. One year data from SYNTAX indicate the incremental risk of
any repeat revascularization was reduced to 7.6%, compared with 17.2% in ARTS, although
differences in inclusion criteria preclude direct comparison. [20]
An additional important consideration is the fact that the heterogeneity of treatment effects
within populations is always of concern when applying trial results to clinical practice. [21]
[22] For patients with less extensive disease or who have a shorter life expectancy, PCI may
be more appealing, with the opposite being true for patients in better general health with
more extensive cardiac disease. As described above in the study methods, ARTS only
included patients with double and triple vessel disease (predominantly double) and excluded
patients with a number of medical complications. The risk-benefit acceptability curves
presented in this analysis are consequently most applicable to relatively healthy patients
with MVD without several other medical complications, a relatively small portion of the
universe of CAD patients. Yet the potential value of the approach for improving information
available for decision-making by physicians and patients remains. Ultimately, as more
comprehensive data are available, risk-benefit determination can become increasingly
personalized.
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Figure 1A: Proportion of patients free from pain after randomization.
Figure 1B: Mean HRQL scores obtained by value weighting EQ-5D results.
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Figure 2A: Risk benefit acceptability curve for incremental risk of additional
revascularization within 3 years versus freedom from pain at 1 month.
Figure 2B: Risk benefit acceptability curve for incremental risk of additional
revascularization within 3 years of randomization versus HRQL benefits at 1 month.
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Table 2





One Year Post-Randomization Clinical Event Risk
Incremental risk of repeat revascularization at 12 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.66 0.91
     Inc. benefit in HRQL, 1 mo 2.7 4.1
Inc. risk of repeat PCI at 12 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.48 0.66
     Inc. benefit in HRQL, 1 mo 2.0 3.0
Inc. risk of repeat CABG at 12 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.23 0.34
     Inc. benefit in HRQL, 1 mo 0.95 1.5
Three Year Post-Randomization Clinical Event Risk
Incremental risk of repeat revascularization at 36 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.81 1.06
     Inc. benefit in HRQL, 1 mo 3.2 4.8
Inc. risk of repeat PCI at 36 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.56 0.76
     Inc. benefit in HRQL, 1 mo 2.3 3.4
Inc. risk of repeat CABG at 36 mo vs
     Inc. benefit in pain free proportion, 1 mo 0.31 0.44
     Inc. benefit in HRQL, 1 mo 1.3 2.0
EuroIntervention. Author manuscript; available in PMC 2011 March 21.
